谷氨酸输注与冠状动脉旁路移植术后急性肾损伤风险的关联:两项随机临床试验的汇总分析
该研究汇总了GLUTAMICS两项前瞻性、随机、双盲多中心试验中791例无糖尿病CABG患者的数据,比较再灌注期静脉输注0.125-M L-谷氨酸与生理盐水对术后急性肾损伤(AKI)的影响。结果显示谷氨酸组AKI风险显著低于对照组(RR 0.49,95%CI 0.29-0.83),多因素分析中保护作用仍显著(OR 0.47,95%CI 0.26-0.86)。谷氨酸组与对照组30天内死亡率分别为0.5%(2/391)与1.0%(4/400),24小时内卒中率分别为0.8%(3/391)与1.8%(7/400)。作者结论为该发现为探索性,需前瞻性试验证实。
要点
- 在无糖尿病的CABG患者中,再灌注期静脉输注0.125-M L-谷氨酸与术后AKI风险显著降低相关(RR 0.49,95%CI 0.29-0.83)。
- 多因素分析中谷氨酸仍与AKI保护作用显著相关(OR 0.47,95%CI 0.26-0.86)。
- 谷氨酸组与对照组需要透析的患者分别为2例与5例。
- 谷氨酸组与对照组30天内死亡率分别为0.5%(2/391)与1.0%(4/400),24小时内卒中率分别为0.8%(3/391)与1.8%(7/400)。
- 作者认为该发现为探索性,需在前瞻性试验中证实。
适用人群与场景
- 无糖尿病的成人患者,患有急性冠脉综合征、左心室射血分数≤0.30或欧洲心脏手术风险评估系统II评分≥3.0,并接受冠状动脉旁路移植术(伴或不伴附加瓣膜手术)。
- 来自瑞典5个心脏手术中心的两项前瞻性、随机、双盲多中心试验,分别于2005年10月4日至2009年11月12日及2015年11月15日至2020年9月30日进行。
诊断标准与关键阈值
- 主要终点AKI定义为术后血浆肌酐升高≥50%,对应RIFLE标准中的Risk期或更高分期。
处置流程与药物剂量
- 再灌注期间静脉输注0.125-M L-谷氨酸或生理盐水,速率1.65 mL/kg/h,持续2小时;之后输注速率减半并额外给予50 mL。
研究设计与关键结果
- 汇总分析纳入791例无糖尿病患者,谷氨酸组391例(平均年龄69.3岁,标准差9.1;女性62例,15.9%),对照组400例(平均年龄69.6岁,标准差9.5;女性73例,18.3%),两组基线数据无差异。
- 谷氨酸与显著降低的AKI风险相关(相对风险0.49,95%CI 0.29-0.83)。
- 谷氨酸组2例、对照组5例需要透析。
- 多因素分析中谷氨酸仍与AKI保护作用显著相关(比值比0.47,95%CI 0.26-0.86)。
- 谷氨酸组与对照组30天内死亡率分别为0.5%(2/391)与1.0%(4/400),24小时内卒中率分别为0.8%(3/391)与1.8%(7/400)。
证据类型、等级与局限
- 证据类型:两项前瞻性、随机、双盲多中心临床试验的汇总分析。
- 作者指出该发现为探索性,需在前瞻性试验中证实。
对床旁实践的改变
- 在无糖尿病的CABG患者中,再灌注期静脉输注0.125-M L-谷氨酸与术后AKI风险显著降低相关(RR 0.49,95%CI 0.29-0.83),但作者认为该发现为探索性,需前瞻性试验证实。
指南或共识出处
- GLUTAMICS(Glutamate for Metabolic Intervention in Coronary Surgery)试验,ClinicalTrials.gov注册号NCT00489827和NCT02592824。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Acute kidney injury (AKI) after cardiac surgery is associated with increased morbidity and mortality, and measures to prevent AKI have had limited success. Glutamate has been reported to enhance natural postischemic recovery of the heart, but not among animals and humans with diabetes.
OBJECTIVE: To summarize pooled results from the GLUTAMICS (Glutamate for Metabolic Intervention in Coronary Surgery) trials regarding the effect of glutamate on postoperative AKI among patients without diabetes undergoing coronary artery bypass graft (CABG) surgery.
DESIGN, SETTING, AND PARTICIPANTS: Data on a total of 791 patients without diabetes from 2 prospective, randomized, double-blind multicenter trials performed at 5 cardiac surgery centers in Sweden between October 4, 2005, and November 12, 2009, and between November 15, 2015, and September 30, 2020, were pooled. Patients had acute coronary syndrome, left ventricular ejection fraction of 0.30 or less, or a European System for Cardiac Risk Evaluation II score of 3.0 or more and underwent CABG with or without additional valve procedure. Statistical analysis was performed from May to November 2023.
INTERVENTIONS: Intravenous infusion of 0.125-M l-glutamic acid or saline at 1.65 mL/kg/h for 2 hours during reperfusion, after which the infusion rate was halved and an additional 50 mL was given.
MAIN OUTCOMES AND MEASURES: The primary end point was AKI, defined as postoperative increase of plasma creatinine of 50% or more, corresponding to the Risk stage or higher in the Risk, Injury, Failure, Loss, and End-Stage kidney disease (RIFLE) criteria.
RESULTS: A total of 791 patients without diabetes (391 who received glutamate [mean (SD) age, 69.3 (9.1) years; 62 women (15.9%)] and 400 controls [mean (SD) age, 69.6 (9.5) years; 73 women (18.3%)]) were randomized. Baseline data did not differ between groups. Glutamate was associated with a significantly lower risk of AKI (relative risk, 0.49 [95% CI, 0.29-0.83]). Dialysis was required for 2 patients in the glutamate group and 5 patients in the control group. In multivariable analysis, glutamate remained significantly associated with a protective effect against AKI (odds ratio, 0.47 [95% CI, 0.26-0.86]). In the glutamate and control groups, the rate of postoperative mortality at 30 days or less was 0.5% (2 of 391) vs 1.0% (4 of 400), and the rate of stroke at 24 hours or less was 0.8% (3 of 391) vs 1.8% (7 of 400).
CONCLUSIONS AND RELEVANCE: In this pooled analysis of 2 randomized clinical trials, infusion of glutamate was associated with a markedly lower risk of AKI after CABG among patients without diabetes. The findings are exploratory and need to be confirmed in prospective trials.
TRIAL REGISTRATION: ClinicalTrials.gov Identifiers: NCT00489827 and NCT02592824.
参考来源
- Holm J, Vanky F, Svedjeholm R, et al. Association of Glutamate Infusion With Risk of Acute Kidney Injury After Coronary Artery Bypass Surgery: A Pooled Analysis of 2 Randomized Clinical Trials. JAMA Netw Open. 2024. PMID: 38252440. doi:10.1001/jamanetworkopen.2023.51743
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。